CD5-targeted CAR-NK therapy
/ Chongqing Precision Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 03, 2025
Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=15 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd
New P1 trial • Hematological Malignancies • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia
1 to 1
Of
1
Go to page
1